PROBLEMATIC ISSUES IN THE EVALUATION OF PHENOTYPIC PROGNOSTIC MARKERS IN OVARIAN GERM-CELL TUMORS

NINO TAVDGIRIDZE; GEORGE TEVDORASHVILI; GEORGE BURKADZE

doi:10.52340/jecm.2021.550

PROBLEMATIC ISSUES IN THE EVALUATION OF PHENOTYPIC PROGNOSTIC MARKERS IN OVARIAN GERM-CELL TUMORS

Authors

NINO TAVDGIRIDZE
GEORGE TEVDORASHVILI
GEORGE BURKADZE

DOI:

https://doi.org/10.52340/jecm.2021.550

Keywords:

Markers, Ovarian germ-cell tumors, Prognosis

Abstract

Ovarian germ-cell tumors represent about 15-20% of all ovarian tumors. They are characterised with high histological and clinical heterogeneity. Ovarian germ-cell tumors can be both benign and malignant. Nowadays, the prognostic markers of ovarian germ-cell tumors are less studied. In particular, there is only limited information about the phenotypic determinants of the malignant transformation of benign germ-cell tumors, as well as lack of information about the relapse development after treatment of malignant germ-cell tumors. In presented review article, the detailed cahracteristics of ovarian germ-cell tumors and the problematic issues in the determination of their prognostic features are discussed.

Downloads

Download data is not yet available.

References

R. L. Siegel and K. D. Miller, “Cancer Statistics , 2020,” vol. 70, no. 1, pp. 7–30, 2020.

S. A. Funt et al., “Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 37, no. 26, pp. 2329–2337, Sep. 2019.

A. Fonseca, A. L. Frazier, and F. Shaikh, “Germ Cell Tumors in Adolescents and Young Adults,” J. Oncol. Pract., vol. 15, no. 8, pp. 433–441, Aug. 2019.

D. M. Berney, S. Stoneham, R. Arora, J. Shamash, and M. Lockley, “Ovarian germ cell tumour classification: views from the testis.,” Histopathology, vol. 76, no. 1, pp. 25–36, Jan. 2020.

M. Lakshmanan et al., “Germ Cell Tumor Ovary: an Institutional Experience of Treatment and Survival Outcomes,” Indian J. Surg. Oncol., vol. 9, no. 2, pp. 215–219, Jun. 2018.

Y. Sato et al., “Late Recurrence in Ovarian Dysgerminoma Presenting as a Primary Retroperitoneal Tumor: A Case Report and Review of the Literature,” Case Rep. Pathol., vol. 2020, p. 4737606, 2020.

L. H. Chen, K.-C. Yip, H.-J. Wu, and S.-B. Yong, “Yolk Sac Tumor in an Eight-Year-Old Girl: A Case Report and Literature Review ,” Frontiers in Pediatrics , vol. 7. p. 169, 2019.

T. Iscar, C. Arean, L. Chiva, and J. Sanz, “Ovarian yolk sac tumor,” Int. J. Gynecol. Cancer, vol. 31, no. 5, pp. 797 LP – 798, May 2021.

D. Nasioudis, E. Chapman-Davis, M. K. Frey, T. A. Caputo, and K. Holcomb, “Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base,” Gynecol. Oncol., vol. 147, no. 2, pp. 296–301, 2017.

G. Mangili et al., “Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.,” Int. J. Gynecol. cancer Off. J. Int. Gynecol. Cancer Soc., vol. 21, no. 8, pp. 1414–1421, Nov. 2011.

L. D. Goyal, B. Kaur, and R. K. Badyal, “Malignant Mixed Germ Cell Tumors of the Ovary: A Series of Rare Cases,” J. Reprod. Infertil., vol. 20, no. 4, pp. 231–236, 2019.

N. S. Safdar, J. N. Stall, and R. H. Young, “Malignant Mixed Germ Cell Tumors of the Ovary: An Analysis of 100 Cases Emphasizing the Frequency and Interrelationships of Their Tumor Types,” Am. J. Surg. Pathol., vol. 45, no. 6, 2021.

L.-Y. Ye, J.-J. Wang, D.-R. Liu, G.-P. Ding, and L.-P. Cao, “Management of giant ovarian teratoma: A case series and review of the literature,” Oncol Lett, vol. 4, no. 4, pp. 672–676, 2012.

H. Sahin, S. Abdullazade, and M. Sanci, “Mature cystic teratoma of the ovary: a cutting edge overview on imaging features,” Insights Imaging, vol. 8, no. 2, pp. 227–241, Apr. 2017.

S. Mandal and B. A. Badhe, “Malignant Transformation in a Mature Teratoma with Metastatic Deposits in the Omentum: A Case Report,” Case Rep. Pathol., vol. 2012, p. 568062, 2012.

G. Mangili et al., “The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors ( MOGTs ): the MITO-9 study Original article,” EGFR Mutat. Adv. non-small-cell lung cancer overall Surviv. data from LUX-Lung 7 trial, vol. 28, no. 2, pp. 333–338, 2017.

B. Kaur, “Pathology of malignant ovarian germ cell tumours,” Diagnostic Histopathol., vol. 26, no. 6, pp. 289–297, 2020.

Y. Chai et al., “Diagnostic Significance of Cellular Neuroglial Tissue in Ovarian Immature Teratoma.,” J. Pathol. Transl. Med., vol. 51, no. 1, pp. 49–55, Jan. 2017.

M. Mazumdar et al., “Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor,” J. Clin. Oncol., vol. 21, no. 14, pp. 2679–2688, Jul. 2003.

J. W. Oosterhuis and L. H. J. Looijenga, “Human germ cell tumours from a developmental perspective,” Nat. Rev. Cancer, vol. 19, no. September, pp. 522–537, 2019.

D. Kurdiani, M. D. T. Cancer, and T. Georgia, “Survival and Reproductive Function After Treatment of dysgerminoma of Ovarian Tumor - case report,” p. 80, 2015.